lupus

Gilead-backed cell therapy startup Kyverna adds fresh funds for new strategy
Gilead-backed cell therapy startup Kyverna adds fresh funds for new strategy
BioPharma Dive
Kyverna Therapeutics
lupus
Gilead Sciences
Treg cell therapy
Flag link:
Amgen’s lupus bets continue to flounder, even those on the Horizon
Amgen’s lupus bets continue to flounder, even those on the Horizon
Fierce Biotech
Horizon Therapeutics
Amgen
lupus
daxdilimab
clinical trials
Flag link:
GSK underscores organ damage risks for lupus patients in It Will campaign
GSK underscores organ damage risks for lupus patients in It Will campaign
Medical Marketing and Media
GSK
DTC ads
lupus
Flag link:
AbbVie's Rinvoq passes midstage test in systemic lupus erythematosus, heads into phase 3
AbbVie's Rinvoq passes midstage test in systemic lupus erythematosus, heads into phase 3
Fierce Pharma
AbbVie
Rinvoq
Humira
systemic lupus erythematosus
lupus
clinical trials
Flag link:
Amgen cuts lupus programs for futility, hours after Lilly officially walks away from one too
Amgen cuts lupus programs for futility, hours after Lilly officially walks away from one too
Fierce Biotech
Amgen
earnings
Eli Lilly
lupus
Flag link:
After gathering enough Nektar, Lilly hands back rights to immunology med post-lupus fail
After gathering enough Nektar, Lilly hands back rights to immunology med post-lupus fail
Fierce Biotech
Eli Lilly
Nektar Therapeutics
Rezpeg
lupus
Flag link:
Fresh layoffs at Nektar Therapeutics as it drops lupus program after phase 2 disappointment
Fresh layoffs at Nektar Therapeutics as it drops lupus program after phase 2 disappointment
Biopharma Reporter
Nektar Therapeutics
lupus
rezpegaldesleukin
layoffs
Rezpeg
Flag link:
New lupus partnership with FDA aims to end drug trials’ history of failure
New lupus partnership with FDA aims to end drug trials’ history of failure
Stat
lupus
FDA
clinical trials
Flag link:
AbbVie clinches back-to-back clinical wins in ulcerative colitis, lupus
AbbVie clinches back-to-back clinical wins in ulcerative colitis, lupus
BioSpace
AbbVie
Skyrizi
ulcerative colitis
lupus
Rinvoq
clinical trials
Flag link:
Nektar's bitter pill: Phase 2 fail ends Lilly-partnered lupus program and prompts eczema rethink
Nektar's bitter pill: Phase 2 fail ends Lilly-partnered lupus program and prompts eczema rethink
Fierce Biotech
Nektar Therapeutics
rezpegaldesleukin
clinical trials
lupus
Flag link:
Gilead, EVOQ Unite on 'Potential Breakthrough' Treatment for RA, Lupus
Gilead, EVOQ Unite on 'Potential Breakthrough' Treatment for RA, Lupus
BioSpace
Gilead Sciences
Evoq Therapeutics
lupus
rheumatoid arthritis
Flag link:
GSK survey finds COVID, lack of early HCP conversations hitting lupus patients' care
GSK survey finds COVID, lack of early HCP conversations hitting lupus patients' care
Fierce Pharma
GSK
lupus
Benlysta
patients
COVID-19
pharma marketing
Flag link:
Biogen’s Antibody Lupus Treatment Shows Mid-Stage Promise
Biogen’s Antibody Lupus Treatment Shows Mid-Stage Promise
BioSpace
Biogen
litifilimab
lupus
systemic lupus erythematosus
monoclonal antibodies
clinical trials
Flag link:
Aria Pharmaceuticals Secures Six Provisional Patents for Pipeline Candidates
Aria Pharmaceuticals Secures Six Provisional Patents for Pipeline Candidates
BioSpace
Aria Pharmaceuticals
patents
lupus
idiopathic pulmonary fibrosis
IPH
chronic kidney disease
Flag link:
Bristol Myers Squibb, with new positive lupus data in hand, readies TYK2 inhibitor for final test
Bristol Myers Squibb, with new positive lupus data in hand, readies TYK2 inhibitor for final test
Fierce Biotech
Bristol Myers Squibb
lupus
psoriasis
deucravacitinib
Flag link:
Seres, Vera Notch Weekend Wins in C.Diff, Lupus Trials
Seres, Vera Notch Weekend Wins in C.Diff, Lupus Trials
BioSpace
Seres Therapeutics
clinical trials
SER-109
C. difficile
Vera Therapeutics
lupus
atacicept
Flag link:
Eli Lilly, Incyte axe Olumiant in lupus amid eczema stalemate at FDA
Eli Lilly, Incyte axe Olumiant in lupus amid eczema stalemate at FDA
Fierce Pharma
Eli Lilly
Incyte
olumiant
FDA
lupus
eczema
Flag link:
Idorsia sets itself up for failure
Idorsia sets itself up for failure
EP Vantage
Idorsia
cenerimod
lupus
clinical trials
Flag link:
AstraZeneca's launch plan for first-in-class lupus med Saphnelo centers on patient-designed support program
AstraZeneca's launch plan for first-in-class lupus med Saphnelo centers on patient-designed support program
Fierce Pharma
AstraZeneca
drug launches
lupus
Saphnelo
patient advocacy groups
Flag link:
AstraZeneca nabs FDA nod to challenge GSK's Benlysta with first-in-class lupus drug Saphnelo
AstraZeneca nabs FDA nod to challenge GSK's Benlysta with first-in-class lupus drug Saphnelo
Fierce Pharma
AstraZeneca
GSK
FDA
lupus
Saphnelo
systemic lupus erythematosus
Benlysta
Flag link:

Pages